Potential biodegradable and organ-specific X-ray contrast agents have been prepared by linking diatrizoic acid to cholesterol and cholic acid, respectively, via a spacer group containing a carbonate double ester. In vitro experiments revealed that the cholic acid esters were enzymatically degraded in the presence of pig liver esterase, while the double esters with cholesterol appeared to be stable, possibly due to low solubility in water.
Introduction
X-ray contrast agents for parenteral use today are triiodinated benzene derivatives with hydrophilic substituents to secure high water-solubility. These agents have similar pharmacokinetic properties such as extracellular distribution and renal elimination. 1, 2 During the past there has been considerable interest in organospecific contrast agents; e.g. agents for liver imaging.
Bile acid drug conjugates, e.g. the anticancer drug chlorambucil, 10, 11 are potential liverspecific targeting drugs. So-called double esters are frequently used in prodrug design because of their high affinity for unspecific esterases. 12 The antibiotic pivampicillin is a typical example. 13 Double esters have also been evaluated in particulate contrast agents. 6 Chloroethoxycarbonyl chloride has been extensively used to prepare linkers in contrast agent such as gas generating polymers. [14] [15] [16] The preparation of potential biodegradable conjugates between diatrizoic acid and the steroids cholesterol and cholic acid, respectively, and evaluation of their degradability in vitro, constitutes the subject of the present report.
Results and Discussion

Synthesis
Epimeric cholest-5-en-3β-yl 1(R,S)-chloroethyl carbonates (2) were prepared in quantitative yield by esterification of cholesterol (1) with (±)-1-chloroethoxycarbonyl chloride according to Dang et al., 17 cf. Scheme 1. The epimeric double esters 3 were subsequently prepared in 66%
yield by esterification of diatrizoic acid as its tetrabutylammonium salt with the chlorocarbonates 2 in DMF, in the presence of catalytic amounts of potassium iodide. t-Butyl cholate (5) was prepared as described by Bonar-Law 18 who first reacted cholic acid (4) with trifluoroacetic anhydride (TFAA) to the corresponding C-24 mixed anhydride and with the C-3 and C-7 hydroxyl groups trifluoromethyl acetylated, cf. Scheme 2. This mixed anhydride was then treated with t-butanol followed by hydrolysis of the C-3 and C-7 trifluoromethyl acetyl groups with aqueous ammonia furnishing t-butyl cholate (5). The C-3 position of t-butyl cholate (5) was selectively [19] [20] [21] O-acylated with (±)-1-chloroethoxycarbonyl chloride to the chlorocarbonate esters 6 in 85% yield. Subsequent esterification of the chlorocarbonates 6 with tetrabutylammonium diatrizoate in DMF using potassium iodide as catalyst, yielded the t-butyl protected esters 7 in 79% yield. Deprotection with TFA furnished the epimeric cholic acid conjugates 8 in 95% yield.
1
H NMR spectra were recorded at 200, 300, and 500 MHz using Varian Gemini 200, Varian XL 300 (manual), and Bruker Avance DRX 500 spectrometers. 13 C NMR spectra were recorded at 50, 75 and 125 MHz using the above mentioned spectrometers.
Assignments of NMR shifts have been limited to the diagnostically important parts, e.g. the contrast agent segment and the spacer (= the 1-chloro-ethoxycarbonate portion). Similarly, we report only assigned 13 C NMR shifts for selected parts of the molecules comprising the contrast agent segment, the spacer and the resonances of C 3 , C 7 , C 12 , C 21 in the steroid moieties.
Additional resolved resonances are listed without assignments. Presented assignments for 1 Hand 13 C NMR spectra are based on published data for relevant compounds. [22] [23] [24] Melting points
were measured with a Reichert melting point microscope and are uncorrected. FAB and EI spectra were obtained using a Trio-2 Mass Spectrometer, VG Biotech Ltd. The EI spectra were recorded using 70 electronvolt ionizing voltage. Electrospray MS was obtained using a Bruker Apex 4.7 instrument. Elemental analyses were performed by Ilse Beetz, Kronach, Germany.
TLC analyses were performed on silica gel plates (Merck 4500).
Cholest-5-en-3β-yl 1(R,S)-chloroethyl carbonates (2). Cholest-5-en-3β-yl 1(R,S)-chlo-roethyl
carbonates (2) were prepared in quantitative yield as described by Dang et al. solution of t-butyl 3α, 7α,12α-trihydroxy-5β-cholan-24-oate (5) (= t-butyl cholate 18 , 1.00 g, 2.2 mmol) and 4-N,N-dimethylaminopyridine (0.36 g, 2.9 mmol) in CH 2 Cl 2 (15 ml). The mixture was stirred for 24 h at room temperature and refluxed for 20 min. The solution was cooled, diluted with CH 2 Cl 2 (100 ml), and washed with saturated aqueous CuSO 4 (100 ml x 4), saturated aqueous NaHCO 3 (100 ml x 2), and brine (100 ml). The organic phase was dried over MgSO 4 .
The solvent was removed under reduced pressure and the product purified by column chromatography on alumina (grade 1, 0.5% MeOH/CHCl 3 ) giving the carbonates 6 as a solid The yield of cholic acid was 98%. Hydrolysis was not observed in the absence of esterase.
The cholesterol derived double esters 3 did not hydrolyze when treated under similar conditions.
